VBIO

Malachite Innovations, Inc. [VBIO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

VBIO Stock Summary

Top 10 Correlated ETFs

VBIO

Top 10 Correlated Stocks

VBIO

In the News

VBIO Financial details

Company Rating
-
Market Cap
0
Income
-784.27K
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
-
P/E
-22.51
Forward P/E
-
PEG
2.75
P/S
-
P/B
22.96
P/C
-
P/FCF
-
Quick Ratio
26.44
Current Ratio
26.54
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.02
EPS next Y
-
EPS next Q
-
EPS this Y
-79.86%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-46.09%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-18.18%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-98%
ROE
-82%
ROC
-2.71%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.36015-0.4195
52W High
-
52W Low
-
RSI
28
Rel Volume
99.47
Avg Volume
98.13K
Volume
9.76M
Perf Week
-43.87%
Perf Month
-67.31%
Perf Quarter
-
Perf Half Y
-85.7%
-
-
-
-
Beta
4.11376
-
-
Volatility
0.05%, 0.1%
Prev Close
-12.22%
Price
0.1602
Change
-7.56%

Something similar

Top by Market Cap
LLY
LLY.SW
VTI
GOOGL
MSFT
Top Correlated ETFs
BKMC
BKSE
BKLC
BKEM
BKIE
Top Correlated Stocks
LEX.L
AAK.ST
SNEX
CAG.ST
FLUI.ST
Similar Market Cap
MGTA
ASTRAL.NS
GDP.L
SRE.L
0E1L.L

Company Profile

Healthcare Biotechnology

Vitality Biopharma, Inc. engages in the development of cannabinoid pharmaceuticals for the treatment of inflammatory disorders in the United States. The company is developing tetrahydrocannabinol glycoside (VBX-100), an oral cannabinoid prodrug for inflammatory bowel disease and irritable bowel syndromes. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. Vitality Biopharma, Inc. was founded in 2007 and is headquartered in Los Angeles, California.